<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00211497</url>
  </required_header>
  <id_info>
    <org_study_id>A99005</org_study_id>
    <nct_id>NCT00211497</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne</brief_title>
  <official_title>A Phase II, Randomized, Vehicle-Controlled, Double-Blind, Multi-Center Study to Evaluate Safety and Efficacy of MBI 226 1.25% and 2.5% Acne Solutions Applied Topically for 12 Weeks to Subjects With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioWest Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioWest Therapeutics Inc</source>
  <brief_summary>
    <textblock>
      This is a Phase II, randomized, vehicle-controlled, double-blind, multi center study to
      evaluate the efficacy and safety of topically applied MBI 226 1.25% and 2.5% Acne Solutions
      as anti-acne preparations in human subjects with facial acne vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date>September 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- percent change from Baseline to Week 12 in inflammatory acne lesion counts</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single continuous endpoints:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Percent change from Baseline to Week 6 and Week 12 in non inflammatory acne lesion counts</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• The percent change from Baseline to Week 6 and Week 12 in total acne lesion counts</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple continuous endpoints:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Percent change from Baseline to Weeks 3, 6, 9 and 12 in inflammatory acne lesion counts</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Percent change from Baseline to Weeks 3, 6, 9 and 12 in non-inflammatory acne lesion counts</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Percent change from Baseline to Weeks 3, 6, 9 and 12 in total acne lesion counts</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical endpoints:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Dichotomized Physicians Global Severity Assessment scores at Week 6 and Week 12</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• PGSA absolute scores at Week 6 and Week 12</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• PGSA absolute scores over Baseline, Week 6 and Week 12</measure>
  </secondary_outcome>
  <enrollment>255</enrollment>
  <condition>Acne Vulgaris</condition>
  <condition>Acne</condition>
  <condition>Propionibacterium Acnes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBI 226 Acne Solutions</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 12 years and older

          -  Presence of inflammatory and non-inflammatory lesions

        Exclusion Criteria:

          -  Acne conglobata, acne fulminans, or secondary acne (chloracne, drug-induced acne,
             etc.)

          -  Active facial cysts or any nodulocystic lesions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Pankovich</last_name>
    <role>Study Director</role>
    <affiliation>BioWest Therapeutics Inc</affiliation>
  </overall_official>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>September 13, 2005</last_update_submitted>
  <last_update_submitted_qc>September 13, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2005</last_update_posted>
  <keyword>acne vulgaris</keyword>
  <keyword>acne</keyword>
  <keyword>Propionibacterium acnes</keyword>
  <keyword>topical</keyword>
  <keyword>inflammatory</keyword>
  <keyword>non-inflammatory</keyword>
  <keyword>lesion counts</keyword>
  <keyword>lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

